Skip to main content

Table 1 Participant characteristics and types of PIEDs used prior to lockdown

From: Investigating the impact of COVID-19 on performance and image enhancing drug use

 

Sample

Blast-Cruise

OR[t]

95% CI

p value

 

(n = 60)

No (n = 17)

Yes (n = 43)

Mean age

26.69

27.56

26.37

[.616]

-

n.s

Mean BMI

26.20

25.27

26.20

[1.779]

-

n.s

Mean percentage body fat

15.00

15.60

15.13

.119

-0.5,0.6

n.s

Competed in a bodybuilding show (%)

11.7

94.5

86.7

0.4

0.1,3.5

n.s

Heterosexual (%)

95.0

94.5

95.4

1.3

0.1,15.1

n.s

Injectable (%; n)

 Testosterone

70; 42

47.1

79.1

4.3

1.3,14.2

0.007

 Trenbolone

28.3; 17

5.9

37.2

9.5

1.1,78.4

0.007

 Boldenone

23.3; 14

11.8

27.9

2.9

0.5,14.7

n.s

 Drostanolone

16.7; 10

5.9

20.9

4.2

0.5,36.4

n.s

 Stanazolol

13.3; 8

6.3

14.0

2.6

0.3,23.3

n.s

 Nandrolone

13.3; 8

11.8

16.3

1.5

0.3,7.8

n.s

 Methenolone

5; 3

11.8

2.3

0.2

0.1,2.1

n.s

Oral (%; n)

 Oxandrolone

28.3; 17

17.6

32.6

2.3

0.6,9.1

n.s

 Metandienone

25; 15

17.6

27.9

1.8

0.4,7.4

n.s

 Oxymetholone

13.3; 8

5.9

16.3

3.1

0.4,27.4

n.s

 Stanazolol

11.7; 7

5.9

16.3

3.1

.4,27.4

n.s

 Mesterolone

8.3; 5

5.9

9.3

1.6

0.2,15.8

n.s

 Chlorodehydromethyltestosterone

1.7; 1

5.9

0.0

0.3

0.2,0.4

n.s

 Fluoxymesterone

1.7; 1

0.0

2.3

0.7

0.6,0.8

n.s

Other PIEDs (%; n)

 Clenbuterol

16.7; 10

5.9

20.9

4.2

0.5,36.4

n.s

 Human-growth-hormone

10; 6

5.9

11.6

2.1

0.2,19.5

n.s

 Peptides

10; 6

11.8

9.3

0.8

0.1,4.6

n.s

 Insulin

8.3; 5

5.9

9.3

1.6

0.2,15.8

n.s

 Prohormones

8.3; 5

0.0

11.6

0.7

0.6,0.8

n.s

 Selective-androgen-receptor-modulators

6.7; 4

5.9

7.0

1.2

0.1,12.4

n.s

 T3

5; 3

5.9

4.7

0.8

0.1,9.2

n.s

 Insulin-like-growth-factor-1

5; 3

5.9

4.7

0.8

0.1,9.2

n.s

  1. Specific p values available from authors on request